AMANDA KEITH: Open Payments
NPI 1689034514 · DANVILLE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,446 in 74 payments from 24 companies in 2025. Trend: 2023 $294 · 2024 $1,014 · 2025 $1,446
Food & beverage: $1,446
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $243 |
| Novo Nordisk Inc | 8 | $168 |
| PFIZER INC. | 8 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $150 |
| Supernus Pharmaceuticals, Inc. | 6 | $102 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Corcept Therapeutics | 2 | $48 |
| Alkermes, Inc. | 2 | $46 |
| Abbott Laboratories | 2 | $45 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $43 |
Products named: CAPLYTA, NURTEC ODT, VRAYLAR, Qelbree, NEXLETOL, REXULTI, Ozempic, Rybelsus.
Industry payments across VA — which companies pay providers there.
